In multivariable logistic regression analysis using data of all patients with IBD, 2log-transformed serum eotaxin-1 levels (ng/mL) were still significantly associated with an increased odds of clinical response or remission to vedolizumab induction therapy at week 14 (Model 3; OR 2.87, 95% CI: 1.09–7.55). The gene discussed is CCL11; the disease is inflammatory bowel disease.